http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2002137668-A1
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-4853 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-48 |
| filingDate | 2001-07-17-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_3c8be7d21f560bbb4ae61bead86a6dc0 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_6be3e572b157242ef744572e34dd1710 |
| publicationDate | 2002-09-26-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | US-2002137668-A1 |
| titleOfInvention | Compositions and methods for inhibiting endothelial cell proliferation and regulating angiogenesis using cancer markers |
| abstract | Compositions and methods for regulating angiogenic activity wherein the compositions comprise cancer markers including kallikreins such as prostate-specific antigen (PSA), serine protease homologs, or active fragments thereof are provided. Serine proteases and kallikreins exhibit potent antiangiogenic activity on human and other animal cells, particularly endothelial cells. More particularly, PSA, PSA homologs, and inhibitory fragments thereof may be combined with a pharmaceutically acceptable excipient or carrier and used to inhibit angiogenesis and angiogenesis-related diseases such as cancer, arthritis, macular degeneration, and diabetic retinopathy. |
| isCitedBy | http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-8642031-B2 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2008175844-A1 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-8455428-B2 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-9452197-B2 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-8158584-B2 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10059756-B2 |
| priorityDate | 1998-05-22-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 57.